Quick Answer
Aprea Therapeutics, Inc. reported Net Income Loss of -$12.60 million for the year ending 2025.
- Aprea Therapeutics, Inc. showed an increase of +2.8% in Net Income Loss from 2024 to 2025.
- This data is from Aprea Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2017 to 2025), Aprea Therapeutics, Inc.'s Net Income Loss has grown by 17.1%.
- Historical annual values: Fiscal year 2025: -$12.60 million | Fiscal year 2024: -$12.96 million | Fiscal year 2023: -$14.29 million | Fiscal year 2022: -$112.66 million | Fiscal year 2021: -$37.13 million | Fiscal year 2020: -$53.48 million | Fiscal year 2019: -$28.06 million | Fiscal year 2018: -$15.53 million | Fiscal year 2017: -$15.19 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: